Thyroid Eye Disease Therapy: Insights from Viridian Therapeutics’ THRIVE-2 Trial

By João L. Carapinha

January 6, 2025

Welcome to 2025 and Syenza News, where the first two weeks of January are dedicated to Thyroid Awareness. This period focuses on highlighting advancements in thyroid care, especially chronic thyroid eye disease (TED) and the experimental treatment veligrotug (for thyroid eye disease therapy). Discussions will cover new technologies, their economic impact, outcomes research, and access throughout these two weeks.

Analysis of Viridian Therapeutics’ Announcement on Veligrotug

Viridian Therapeutics recently announced positive results from their Phase 3 THRIVE-2 clinical trial of veligrotug for chronic thyroid eye disease.

Key Findings of the THRIVE-2 Trial

Trial Design and Enrollment: The THRIVE-2 trial is a randomized, double-masked, placebo-controlled study with 188 patients. 125 received veligrotug and 63 received a placebo, with treatments administered three weeks apart.

Efficacy Outcomes: The trial successfully met all primary and secondary endpoints at the 15-week primary analysis timepoint. Veligrotug demonstrated statistically significant improvements in key disease endpoints, including:
– Proptosis: Patients treated with veligrotug achieved a Proptosis Responder Rate (PRR) of 56%. Just 8% of patients on placebo achieved the outcome. The mean reduction in proptosis was 2.34mm from baseline in the veligrotug group, versus 0.46mm in the placebo group.
– Diplopia: Among patients treated with veligrotug, 56% showed a response in diplopia. 32% achieving complete resolution compared to 25% and 14% in the placebo group, respectively.
– Clinical Activity Score (CAS): 54% of veligrotug patients achieved a maximal or near-maximal therapeutic effect on CAS. Researchers defined a maximal or near-maximal therapeutic effect on CAS as reaching a score of 0 or 1, contrasting it with 24% of patients in the placebo group. The mean reduction in CAS was 2.9 from baseline for veligrotug patients, compared to 1.3 for placebo patients.

Safety Profile: Researchers found that veligrotug was well-tolerated and matched the safety profile of earlier studies. There was a low incidence of hearing impairment – 12.8% vs. 3.2% in the placebo group.

Implications and Future Plans

Treatment Potential: The promising results from the THRIVE trials suggest veligrotug could become the preferred treatment for all types of active and chronic TED.

Future Clinical Trials: Viridian Therapeutics is running two global Phase 3 trials, REVEAL-1 and REVEAL-2, for VRDN-003, a new veligrotug formulation. Viridian Therapeutics expects topline results from the Phase 3 trials by mid-2026 and plans to submit a Biologics License Application by late 2026.

Conclusion

THRIVE-2 trial results show significant progress in treating chronic thyroid eye disease, offering new hope and emphasizing the importance of continued research in thyroid care.

Reference url

Recent Posts

Argentina WHO Withdrawal
   

Argentina WHO Withdrawal: President Milei Exits Global Health Alliance Amid COVID-19 Disputes

💡 *What happens when a country decides to withdraw from global health organizations?*
Argentina’s President Javier Milei has made the bold move to withdraw from the WHO, citing significant disagreements over health management during the pandemic. This decision raises questions about national sovereignty, cooperation, and the future of global health initiatives. Dive into the implications of Argentina’s stance and what it means for international health governance.

#SyenzaNews #globalhealth #healthcarepolicy

Gauteng HPV vaccination campaign
      

Gauteng HPV Vaccination Campaign: Protecting Girls Against Cervical Cancer

💉 Ready to protect our future generations from cervical cancer?

The Gauteng HPV vaccination campaign aims to vaccinate grade 5, 6, and 7 girls against the virus that causes most cervical cancers. By leveraging a single-dose regimen, this initiative not only enhances access to life-saving vaccines but also strives to meet ambitious global health targets.

Explore how this campaign is reshaping health outcomes in South Africa and why parental consent is key to its success.

#SyenzaNews #HealthEconomics #HealthcareInnovation #UniversalHealthCoverage

Capvaxive vaccine approval
     

Capvaxive Vaccine Approval

🌍 What if a single vaccine could significantly change the landscape of pneumococcal disease prevention in adults?

The European Medicines Agency has just recommended Merck’s Capvaxive, an innovative 21-valent pneumococcal conjugate vaccine! With robust data from multiple phase 3 trials, this potential approval marks a pivotal step in the fight against invasive Streptococcus pneumoniae infections in the EU. Look into how Capvaxive could enhance public health outcomes and offer extensive serotype coverage.

#SyenzaNews #pharmaceuticals #healthcarepolicy

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.